Want to join the conversation?
For remainder of 2015, $ABBV sees revenue performance to be driven by strong growth from HUMIRA, global launch of interferon-free HCV treatment, and revenue growth in certain key products including Creon and Duodopa. IMBRUVICA, acquired through the acquisition of Pharmacyclics, will also be significant contributor to revenue growth in 2015.
$AGIO plunge 15%.. what's happening... is this going for a toss !
Does anyone feel $SBUX CEO Schultz stepping down could prove a disaster for the company?
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.